Yuanqi Biotechnology

Yuanqi Biomedical is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, dedicated to developing innovative small molecule therapeutics for oncology and autoimmune diseases. Founded in 2019, the company utilizes a proprietary drug discovery platform to target high-value kinases with high selectivity. Its lead program, YQ-001, is a dual TYK2/JAK1 inhibitor currently in Phase 2 clinical trials for the treatment of psoriasis and other inflammatory conditions. The pipeline also includes YQ-013, a potent HPK1 inhibitor in Phase 1 development for advanced solid tumors, and several preclinical programs. Yuanqi Biomedical has attracted significant investment from leading venture capital firms such as Qiming Venture Partners, GL Ventures, and TF Capital.